Abid is the Chief Financial Officer of Artios and leads the company’s financial, investor relations, and public relations operations.  Abid brings 18 years of finance experience in life science businesses to Artios.

Prior to joining Artios, he was CFO of Precision BioSciences (NASDAQ: DTIL), a next generation genome editing company.  There he helped the company raise over $300M in capital, including a $146M IPO and $110M Series B.  Abid also worked at GlaxoSmithKline for five years in deal finance and portfolio management roles.  There he worked on the divestment of Ofatumumab to Novartis for $1B, the acquisition of the BMS HIV portfolio for up to $1.4B, and the in-license cell & gene therapy deal with Adaptimmune.  Abid also spent 5 years at MedImmune LLC in commercial and capital finance roles.

Abid holds a Bachelor of Science degree in chemical engineering and a master of business administration, both from Purdue University.  He is also a Certified Public Accountant.